
## Jenny H J Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1842046/publications.pdf Version: 2024-02-01



IENNY HILEE

#	Article	IF	CITATIONS
1	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Frontiers in Oncology, 2022, 12, 820510.	2.8	2
2	Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 157, 103187.	4.4	17
3	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 2020, 26, 5926-5933.	7.0	41
4	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers, 2020, 12, 3374.	3.7	27
5	Dosing of BRAF and MEK Inhibitors in Melanoma: No Point in Taking a Break. Cancer Cell, 2020, 38, 779-781.	16.8	3
6	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Cancers, 2020, 12, 2228.	3.7	22
7	Methylated circulating tumor DNA as a biomarker in cutaneous melanoma. Melanoma Management, 2020, 7, MMT46.	0.5	7
8	Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. Clinical Lung Cancer, 2020, 21, 378-383.e1.	2.6	8
9	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2020, 26, 4064-4071.	7.0	50
10	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	12.8	165
11	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. Cancers, 2019, 11, 1905.	3.7	14
12	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy. Clinical Cancer Research, 2019, 25, 1557-1563.	7.0	249
13	Monitoring Melanoma Using Circulating Free DNA. American Journal of Clinical Dermatology, 2019, 20, 1-12.	6.7	26
14	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
15	Metastasisâ€specific patterns of response and progression with antiâ€< scp>PDâ€1 treatment in metastatic melanoma. Pigment Cell and Melanoma Research, 2018, 31, 404-410.	3.3	34
16	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies. JAMA Oncology, 2018, 4, 717.	7.1	229
17	Evaluation of commercial kits for purification of circulating free DNA. Cancer Genetics, 2018, 228-229, 21-27.	0.4	90
18	Liquid biomarkers in melanoma: detection and discovery. Molecular Cancer, 2018, 17, 8.	19.2	74

Jenny H J Lee

#	Article	IF	CITATIONS
19	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 2017, 5, 32.	6.8	33
20	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	1.8	278